Novel Indoline Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness and CNS Disorders.
ACS Med Chem Lett January 23, 2025 Ram W. Sabnis, Anika R. Sabnis 3 citations
No Summary
Ram W. Sabnis
4 papers in the library · 3 citations · publishing 2025-2026
Papers
Novel Indoline Derivatives Serotonergic Psychedelic Agents as 5‑HT2A Agonists for Treating Psychosis, Mental Illness and CNS Disorders.
ACS Med Chem Lett April 27, 2026 Ram W. Sabnis, Anika R. Sabnis
No Summary
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.
ACS Med Chem Lett February 13, 2025 Ram W. Sabnis, Anika R. Sabnis
The text describes novel tryptamine compounds that act as agonists at the 5-HT2A receptor, a serotonin receptor subtype, for potential treatment of mood disorders including depressive disorders and bipolar disorders. The work presents these compounds as a therapeutic approach, but no specific findings, experimental results, or clinical data are reported.
Novel 3-Cycloaminoindole Compounds as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.
ACS Med Chem Lett January 4, 2025 Ram W. Sabnis
The text describes a class of novel chemical compounds, 3-cycloaminoindoles, that act as serotonergic psychedelic agents. These compounds are proposed for potential therapeutic use in treating psychosis, mental illness, and other central nervous system (CNS) disorders. The abstract indicates the compounds are designed to interact with serotonin receptors, a common target for psychedelic and psychiatric drugs, but provides no experimental data, results, or evidence of efficacy.